Edition:
United States

Alkermes Plc (ALKS.O)

ALKS.O on Nasdaq

58.16USD
28 Jun 2017
Change (% chg)

$1.04 (+1.82%)
Prev Close
$57.12
Open
$57.51
Day's High
$58.32
Day's Low
$57.07
Volume
537,921
Avg. Vol
860,350
52-wk High
$63.40
52-wk Low
$40.63

ALKS.O

Chart for ALKS.O

About

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central... (more)

Overall

Beta: 2.25
Market Cap(Mil.): $8,750.24
Shares Outstanding(Mil.): 153.19
Dividend: --
Yield (%): --

Financials

  ALKS.O Industry Sector
P/E (TTM): -- 240.52 19.05
EPS (TTM): -1.32 -- --
ROI: -12.94 -8.03 -5.05
ROE: -16.11 -10.41 -4.28

BRIEF-Alkermes announces initiation of study 217 for ALKS 5461

* Alkermes announces initiation of study 217 for ALKS 5461 for treatment of major depressive disorder

Jun 12 2017

BRIEF-Alkermes initiates phase 3 study of ALKS 3831 in young adult patients

* Alkermes announces initiation of phase 3 study of alks 3831 in young adult patients

Jun 08 2017

BRIEF-Alkermes CEO Richard Pops' 2016 total compensation was $9.6 mln vs $12.4 mln in 2015

* CEO Richard Pops' 2016 total compensation was $9.6 million versus $12.4 million in 2015 - sec filing Source text (http://bit.ly/2p9SZ48) Further company coverage:

Apr 13 2017

BRIEF-Alkermes Q4 non-gaap earnings per share $0.15

* Alkermes plc reports financial results for the year ended dec. 31, 2016 and provides financial expectations for 2017

Feb 15 2017

More From Around the Web

Competitors

Earnings vs. Estimates